MARKET

FGEN

FGEN

Fibrogen Inc
NASDAQ
7.69
+0.54
+7.55%
Closed 16:00 07/14 EDT
OPEN
7.09
PREV CLOSE
7.15
HIGH
7.77
LOW
7.03
VOLUME
33.83K
TURNOVER
--
52 WEEK HIGH
38.25
52 WEEK LOW
4.500
MARKET CAP
31.08M
P/E (TTM)
-3.0341
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at FGEN last week (0707-0711)?
Weekly Report · 22h ago
ProKidney Corp. Skyrockets 515% on Trial Data, But is it a Buy?
Barchart · 6d ago
Stock Market Today: PROK Soars 515% on Surging Volume Amid Clinical Trial Buzz
The Motley Fool · 6d ago
Weekly Report: what happened at FGEN last week (0630-0704)?
Weekly Report · 07/07 09:07
Director Makes Bold Move with Major FibroGen Stock Purchase
TipRanks · 07/03 02:03
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 07/02 21:05
Weekly Report: what happened at FGEN last week (0623-0627)?
Weekly Report · 06/30 09:07
Weekly Report: what happened at FGEN last week (0616-0620)?
Weekly Report · 06/23 09:07
More
About FGEN
FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).

Webull offers FibroGen Inc stock information, including NASDAQ: FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.